Results of MARTINEX and University of Montreal Collaboration Redefine Concepts in Dermal Fillers

The International Research and Development Center for Innovative Technologies (Martinex ANO IRCIT) and the University of Montreal (Université de Montréal, Canada) announce the results of their joint work. The Russian biotechnological manufacturing company and developer of premium aesthetic medicine solutions, together with one of the world's leading research centers, have created a fundamentally new class of bioengineered materials for dermal contouring. They are based on the patented CROSS-MODUL^™ technology, which has proven its effectiveness within the Hyaluform^® platform.

While working on creating the ideal dermal filler, specialists from Martinex IRCIT and the University of Montreal set themselves an ambitious task. They aimed to combine in one product qualities previously considered incompatible: predictable volume stability and natural integration with tissues. Until recently, practitioners faced a difficult choice: to use highly elastic fillers for pronounced support or more malleable gels for a subtle, natural result. The CROSS-MODUL^™ technology resolves this dilemma by combining both properties in one solution.

The engineering concept of the technology is based on creating a hybrid gel architecture:

• An elastic matrix ensures smooth, controlled distribution and natural integration with tissues.
• Thousands of ultra-dense particles, evenly distributed within the structure, form an internal supporting framework. It guarantees volume stability and a pronounced lifting effect without the risk of migration.

"We no longer talk about an 'either-or' choice. With CROSS-MODUL^™ technology, doctors will get a dermal filler that is simultaneously stable and malleable. Essentially, it's a combination of the benefits of biphasic and monophasic gels in one syringe. For the patient, this means a natural, long-lasting result with minimal recovery time," notes Natalia Mikhailova, Ph.D. in Medical Sciences, Scientific Director of MARTINEX.

A New Level of Safety and Comfort

Thanks to mechanochemical synthesis and fully automated production, Hyaluform^® fillers based on CROSS-MODUL^™ contain a record low amount of the residual cross-linking agent BDDE — less than 0.1 ppm, setting a new safety standard in the industry.

The platform's physiological parameters — pH 7.4 and osmolarity 290 mOsm/kg — closely match the characteristics of the skin. This ensures comfort during injections, reduces pain, minimizes the risk of edema, and shortens the recovery period.

International Recognition

The Hyaluform^® platform, created based on CROSS-MODUL^™, has already gained international recognition, becoming the first Russian injectable product registered in the European Union as a medical device (CE Mark). This serves as independent confirmation of the high level of quality, safety, and efficacy of the products.

The collaboration between Martinex IRCIT and the University of Montreal will continue, including further research and the development of new products based on CROSS-MODUL^™ technology.